Last updated: May 28, 2026
Eysuvis (loteprednol etabonate ophthalmic suspension) is supplied in the US under Bausch + Lomb’s brand ownership. Corporate sourcing and FDA manufacturing-site assignments typically determine which contract manufacturers (API and drug product) supply clinical and commercial lots, while distributor networks control warehouse-to-pharmacy flow.
What matters for suppliers is the FDA manufacturing-site and labeling-chain details. Without the Eysuvis specific FDA listing (NDC-to-manufacturing site) and the Orange Book/Biologics equivalents (not applicable here), supplier identification can’t be completed to a level suitable for R&D, licensing, or litigation decisions.
Who supplies Eysuvis in the US supply chain?
Eysuvis is marketed in the US by Bausch + Lomb, with the product manufactured at FDA-registered drug-product manufacturing sites and distributed through branded pharmaceutical channels.
What entities are typically “suppliers” for an ophthalmic suspension?
- Brand owner and marketing authorization holder (labeler)
- Drug-product manufacturer(s) (fill, finish, packaging)
- API manufacturer(s) (loteprednol etabonate bulk)
- Repackagers or secondary packagers (if applicable)
- Wholesalers and specialty distribution partners (logistics layer)
Why “supplier” must be mapped to FDA sites
For ophthalmics, the same labeled product can be produced on different lines or by multiple contract manufacturers across NDCs and time periods. Supplier risk changes by lot, NDC, and manufacturing site.
Which contract manufacturers make Eysuvis drug product?
Not determinable from the information provided.
Correct identification requires the Eysuvis FDA listing that ties each NDC to the exact manufacturer name(s) and address(es) for drug product and labeling operations.
What you need to confirm for supplier onboarding or IP work
- NDC-specific manufacturer name and site address
- Contract manufacturing scope (drug substance vs drug product)
- Packaging configuration (bottle size, dropper assembly, carton)
- Labeler vs manufacturer split (common in ophthalmics)
Who produces loteprednol etabonate (API) for Eysuvis?
Not determinable from the information provided.
Loteprednol etabonate API sourcing can involve multiple suppliers depending on scale, supply contracts, and compliance history.
Typical API-sourcing patterns in ophthalmic steroids
- Single-source API is common for niche ophthalmic actives
- Transition to secondary API sources happens when supply tightens or for redundancy
- API changes may require comparability/CMC updates depending on regulatory approvals
What is the Orange Book status of Eysuvis, and does it indicate supplier relationships?
Orange Book status cannot be used to derive suppliers directly.
Orange Book lists patents and exclusivity, not drug-product manufacturing contractors. For suppliers, the binding sources are FDA listing data and labeler/manufacturer assignments.
Does any patent list correlate to commercial supply?
Patent estates can correlate to original development and commercialization partners, but they do not map to current contract manufacturing without an NDC-to-site record.
What generic entry risks matter for Eysuvis suppliers?
Supplier risk is tied to whether generics or ANDA filers are attempting to enter via bioequivalent ophthalmic formulations, and whether Eysuvis has formulation or method-of-use IP barriers.
Are there FDA-approved generic or follow-on versions?
Not determinable from the information provided. Without the Eysuvis NDC list and FDA product activity record, there is no basis to state competitive product presence or timelines.
Key takeaways
- “Suppliers for Eysuvis” in a defensible way requires NDC-level mapping to FDA-registered manufacturer(s) and labeler/distributor chain.
- Bausch + Lomb is the brand marketer/labeler in the US, but the contract manufacturing and API supply chain cannot be identified from the information provided.
- Patent status does not directly identify manufacturing suppliers.
FAQs
- How do I identify Eysuvis manufacturing sites by NDC?
- Which FDA listing fields show the drug-product manufacturer for Eysuvis?
- Do Eysuvis batches come from multiple contract manufacturers?
- How can Eysuvis supplier changes affect ANDA comparability packages?
- What distributor channels typically move ophthalmic suspension products like Eysuvis in the US?
References
- FDA. Drugs@FDA (product label, NDC listing, and manufacturing site data). U.S. Food and Drug Administration. (Accessed via Drugs@FDA).
- FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations (Eysuvis/loteprednol etabonate listings). U.S. Food and Drug Administration. (Accessed via Orange Book).
